ClinicalTrials.gg
CompletedNCT01301092Updated Oct 7, 2014Results posted

A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

A Phase 1 interventional study of LY2189265 in Diabetes Mellitus, Type II, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
46th of 54
30 · median 159
Started
2011
with 7 others
Phase 1
15 of 54
none open now
Registered
13th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 46th largest by enrollment, is one of 8 that started in 2011, is one of 15 in phase 1, and was the 13th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

LY2189265 is an investigational drug being developed for the treatment of type 2 diabetes mellitus. This study will compare the concentrations of LY2189265 using different methods of administration: subcutaneous (or SC- an injection just under the skin), intravenous (or IV - into a vein in the arm) and intramuscular (IM - into the muscle of the left thigh). The purpose of this study is to look at how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given by the methods above. The study is divided into three parts, Part A, B and C. Volunteers will only be able to participate in one part. All Participants in Part A will receive a single IV dose of up to 0.1 milligram (mg). Participants in Part B will be given drug twice by IV and an SC injection (1.5 mg). Part B of the study will occur after Part A because the dose of IV drug will depend on the results of Part A. Part B of the study may not occur if the volunteers in Part A do not tolerate the drug. Participants in Part C will also be given drug twice by an SC injection and an IM injection, both doses will be 0.75 mg.

03

Conditions studied

  • Diabetes Mellitus, Type II
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined by medical history and physical examination.
  • Male subjects with female partners of , or partners who are pregnant or breastfeeding, agree to use a reliable method of from the time of the first dose until 3 months after the last dose of product, as determined by the investigator. The method may be one of the following: condom with spermicidal agent, male subject sterilization, true abstinence (which is in line with the subject's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable).
  • Female subjects not of child-bearing potential (that is, are or permanently sterilized [for example, tubal occlusion, hysterectomy, bilateral salpingectomy]). Such subjects will not be required to use contraception but must test negative for pregnancy at the time of enrollment. Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) with follicle stimulating hormone (FSH) greater than or equal to 40 milli-international units per milliliter (mIU/mL).
  • Female subjects who have undergone sterilization by tubal ligation: agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such subjects must also test negative for pregnancy at the time of enrollment.
  • Have a (BMI) of between 23.0 and 35.0 kilogram/square meter (kg/m²), inclusive.
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not by the investigator.
  • Have normal sitting blood pressure and pulse rate as determined by the investigator, or with changes compatible with their age.
  • Have venous access sufficient to allow for blood sampling and/or IV administration of investigational product as per the protocol.
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
  • Have given written approved by Lilly and the ethical review board (ERB) governing the site.

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Are women of child bearing potential
  • Have known allergies to Glucagon-like peptide-1 (GLP-1)-related compounds including LY2189265.
  • Are persons who have previously completed or withdrawn from this study or any other study investigating LY2189265.
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study.
  • Have a history or presence of gastrointestinal disorder (including pancreatitis [history of chronic pancreatitis or idiopathic acute pancreatitis] or gall bladder disease), or gastrointestinal disease that impacts gastric emptying (GE) (for example, gastric bypass surgery, pyloric stenosis) or could be aggravated by GLP analogs (for example, esophageal reflux). Subjects having had cholecystolithiasis (removal of gall stones), cholecystectomy (removal of gall bladder) and/or appendectomy in the past with no further sequelae may be included in the study at the discretion of the screening physician.
  • Have a history or presence of significant active neuropsychiatric disease
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
  • Show evidence of (HIV) and/or positive human HIV antibodies.
  • Show evidence of and/or positive hepatitis C antibody.
  • Show evidence of and/or positive hepatitis B surface antigen.
  • Are women with a positive pregnancy test or women who are lactating.
  • Use or intend to use over-the-counter medication other than paracetamol within 7 days prior to dosing or prescription medication (with the exception of vitamin/mineral supplements and/or hormone replacement therapy and/or thyroid replacement therapy) within 14 days prior to dosing.
  • Have donated blood of more than 500 mL within the last month.
  • Are subjects who have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), (1 unit = 12 ounce [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits), or are unwilling to stop alcohol consumption from at least 24 hours prior to screening and each dose, and while resident at the clinical research unit (CRU).
  • Are subjects who smoke more than 10 cigarettes per day, are unwilling to refrain from smoking on the day of LY2189265 administration and while resident.
  • Are subjects who, in the opinion of the investigator, are in any way unsuitable to participate in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Part A: LY2189265 intravenous

    Single intravenous (IV) dose, starting at 0.1 milligrams (mg) of LY2189265. Dose may be increased to 0.2 mg or decreased to 0.05 mg for subsequent patients, dependent on safety assessments of the first 3 patients.

    Biological: LY2189265

  • Experimental
    Part B: LY2189265 subcutaneous, intravenous

    Patients are randomized to 2 sequences of 2 treatments. Single 1.5 mg subcutaneous (SC) dose of LY2189265 in Period 1; single intravenous (IV) dose of LY2189265 (determined by Part A IV arm data) in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.

    Biological: LY2189265

  • Experimental
    Part C: LY2189265 subcutaneous, intramuscular

    Patients are randomized to 2 sequences of 2 treatments. Single 0.75 mg subcutaneous (SC) dose of LY2189265 in Period 1; single 0.75 mg intramuscular (IM) of LY2189265 in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.

    Biological: LY2189265

Interventions

  • BiologicalLY2189265

    administered intravenous, subcutaneous or intramuscular

06

What researchers measure

Primary outcomes

  1. Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV)

    AUC is AUC from time zero to infinity. The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for participants, sequence, treatment, period and random error.

    Time frame: Predose up to 336 hours postdose

  2. Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV)

    The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for participants, sequence, treatment, period and random error.

    Time frame: Predose up to 336 hours postdose

Secondary outcomes

  1. Area Under the Concentration Time Curve (AUC) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)

    AUC is AUC from time zero to infinity. The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for participants, sequence, treatment, period and random error.

    Time frame: Predose up to 336 hours postdose

  2. )Maximum Concentration (Cmax) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)

    The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for participants, sequence, treatment, period and random error.

    Time frame: Predose up to 336 hours postdose

07

Results

Posted Oct 7, 2014

Participant flow

Participant flow — Overall Study
MilestonePart A: LY2189265 IntravenousPart B: LY2189265 Subcutaneous, IntravenousPart C: LY2189265 Subcutaneous, Intramuscular
Started6168
Completed6167
Not completed001
Withdrew: Lost to follow-up001

Outcome measures

PrimaryDose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV)

AUC is AUC from time zero to infinity. The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for participants, sequence, treatment, period and random error.

Time frame:
Predose up to 336 hours postdose
Reported as:
Geometric mean · nanograms*hour/milliliter/milligram
Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV)
nanograms*hour/milliliter/milligramPart B: LY2189265 SubcutaneousPart B: LY2189265 Intravenous
Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV)10256 (8964 to 11734)23150 (20234 to 26485)
Statistical analysis
  • Part B: LY2189265 Subcutaneous vs Part B: LY2189265 Intravenous · Mixed Linear effects model analyses · Ratio of geometric ls mean: 0.443 · 90% CI 0.395 to 0.497
PrimaryMaximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV)

The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for participants, sequence, treatment, period and random error.

Time frame:
Predose up to 336 hours postdose
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV)
nanograms/milliliter (ng/mL)Part B: LY2189265 SubcutaneousPart B: LY2189265 Intravenous
Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV)80.7 (71.8 to 90.8)38.3 (34.1 to 43.1)
Statistical analysis
  • Part B: LY2189265 Subcutaneous vs Part B: LY2189265 Intravenous · Mixed Linear effects model analyses · Ratio of geometric ls mean: 2.10 · 90% CI 1.84 to 2.41
SecondaryArea Under the Concentration Time Curve (AUC) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)

AUC is AUC from time zero to infinity. The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for participants, sequence, treatment, period and random error.

Time frame:
Predose up to 336 hours postdose
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*h/mL)
Area Under the Concentration Time Curve (AUC) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)
nanograms*hour/milliliter (ng*h/mL)Part C: LY2189265 IntramuscularPart C: LY2189265 Subcutaneous
Area Under the Concentration Time Curve (AUC) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)9828 (7525 to 12837)10215 (7832 to 13323)
Statistical analysis
  • Part C: LY2189265 Intramuscular vs Part C: LY2189265 Subcutaneous · Mixed Linear effects model analyses · Ratio of geometric ls means: 0.962 · 90% CI 0.858 to 1.08
Secondary)Maximum Concentration (Cmax) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)

The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for participants, sequence, treatment, period and random error.

Time frame:
Predose up to 336 hours postdose
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
)Maximum Concentration (Cmax) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)
nanograms/milliliter (ng/mL)Part C: LY2189265 IntramuscularPart C: LY2189265 Subcutaneous
)Maximum Concentration (Cmax) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)56.9 (48.4 to 67.0)54.2 (46.3 to 63.5)
Statistical analysis
  • Part C: LY2189265 Intramuscular vs Part C: LY2189265 Subcutaneous · Mixed Linear effects model analyses · Ratio of geometric ls means: 1.05 · 90% CI 0.924 to 1.19

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: 0.1 mg IV LY2189265—0/6 (0%)0/6 (0%)
Part B: 0.1 mg IV LY2189265—0/16 (0%)7/16 (43.8%)
Part B: 1.5 mg SC LY2189265—0/16 (0%)9/16 (56.3%)
Part C: 0.75 mg IM LY2189265—0/8 (0%)3/8 (37.5%)
Part C: 0.75 mg SC LY2189265—0/8 (0%)2/8 (25%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPart A: 0.1 mg IV LY2189265Part B: 0.1 mg IV LY2189265Part B: 1.5 mg SC LY2189265Part C: 0.75 mg IM LY2189265Part C: 0.75 mg SC LY2189265
HeadacheNervous system disorders0/62/166/161/80/8
DyspepsiaGastrointestinal disorders0/60/163/160/82/8
Decreased appetiteMetabolism and nutrition disorders0/60/163/160/80/8
NauseaGastrointestinal disorders0/61/162/160/81/8
VomitingGastrointestinal disorders0/60/161/161/81/8
Muscle spasmsMusculoskeletal and connective tissue disorders0/60/160/161/80/8
DizzinessNervous system disorders0/60/160/161/80/8
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/60/160/161/80/8
Abdominal painGastrointestinal disorders0/60/161/160/80/8
Gastrooesophageal reflux diseaseGastrointestinal disorders0/60/161/160/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A: LY2189265 IntravenousPart B: LY2189265 Subcutaneous, IntravenousPart C: LY2189265 Subcutaneous, IntramuscularTotal
Mean47.0 ± 13.142.3 ± 15.045.6 ± 16.644.10 ± 14.71
Sex: Female, Male
Sex: Female, Male(Participants)Part A: LY2189265 IntravenousPart B: LY2189265 Subcutaneous, IntravenousPart C: LY2189265 Subcutaneous, IntramuscularTotal
Female34310
Male312520
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: LY2189265 IntravenousPart B: LY2189265 Subcutaneous, IntravenousPart C: LY2189265 Subcutaneous, IntramuscularTotal
Hispanic or Latino1001
Not Hispanic or Latino516829
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: LY2189265 IntravenousPart B: LY2189265 Subcutaneous, IntravenousPart C: LY2189265 Subcutaneous, IntramuscularTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0235
White614525
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Part A: LY2189265 IntravenousPart B: LY2189265 Subcutaneous, IntravenousPart C: LY2189265 Subcutaneous, IntramuscularTotal
United States616830
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Evansville, Indiana, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2011
First posted
Feb 23, 2011
Start
Feb 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01301092
Responsible party
Sponsor
First posted
Feb 23, 2011
Start date
Feb 2011
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion